At this time, New York Oncology Hematology does not have access to acquire and administer the new COVID prophylaxis shot Evusheld for immunocompromised patients. We await further guidance from NYS and will keep our patients updated.

About Us

Dr. Weissman on Keytruda

9/10/2014

New York Oncology Hematology’s Dr. Charles Weissman, an expert on melanoma, speaks with Newschannel 13 health reporter Benita Zahn about the groundbreaking FDA approval of anti-cancer drug Keytruda.

Jack Lewis, a patient of Dr. Weissman’s, who is currently participating in a clinical trial through New York Oncology Hematology for another melanoma treatment, shares his story and why he believes the clinical trial treatment is helping him live a longer life.

With the largest, most comprehensive clinical trial program in the region, New York Oncology Hematology and our patients have played a pivotal role in FDA approval of 38 anti-cancer drugs over the past 20 years.